News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors: Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@icrinc.com

April 9, 2020 Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC)

Sirnaomics Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer…

March 20, 2020 Industry, academia pivot: Pipeline of COVID-19 vaccine and therapeutic candidates doubles

A list of biopharma companies and nonprofit entities, including academia, working feverishly to find a vaccine or…

February 19, 2020 Hunt for New Coronavirus Treatments Includes Gene-Silencing and Monoclonal Antibodies

Viral infections can be very hard to treat. Just ask anyone who has a bad case of…

February 10, 2020 Sirnaomics’ siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the…

January 28, 2020 Sirnaomics to develop RNAi-based therapeutics for 2019-nCoV infections

The outbreak of 2019-nCov infection, which causes respiratory illness, was first detected in Wuhan City, China, and…

1 2 3 10